New Frontiers in the Management of
Hepatocellular Carcinoma (HCC): Exploring Novel Treatment Advances
and Approaches
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2018 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from July 17, 2018 to August 1, 2019 |
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Eisai, and Exelixis
Description:
Hepatocellular carcinoma (HCC) is the most common type of liver
cancer, accounting for about 90% of cases of primary liver cancer in
the United States. The prevalence and mortality rate of liver cancer
has been rising steadily over the past decade and is still
increasing as death rates are rising faster than any other type of
cancer. Prognosis is especially poor for those with unresectable HCC.
Fortunately, new agents have become available for the first time in
almost 10 years, including targeted therapies such as Tyrosine
Kinase Inhibitors (TKIs). These regimens have shown the ability to
improve safety and efficacy outcomes, especially in patients with
disease progression and may fulfill the unmet need of treatment,
particularly beyond first-line setting.
Upon Completion of this
activity, participants will be able to:
-
Analyze the safety and efficacy
profiles of current and emerging immunotherapies or targeted
therapies in the treatment of advanced hepatocellular carcinoma
(HCC)
-
Discuss the relative benefits and
limitations of immunotherapies for HCC beyond first-line therapy
-
Explore emerging clinical trial data
on the use of biomarkers and immune checkpoint inhibitors in the
management of HCC
-
Identify patients with HCC for whom
an immunotherapy is an appropriate choice for the next step in
the management of their cancer
-
Examine immune-related adverse
events associated with the immunotherapies indicated for the
treatment of patients with HCC in order to maximize tolerability
and patient adherence
Faculty: |
David E. Kaplan, MD, MSc,
FACP
Associate Professor of Medicine
Perelman School of Medicine at the University of
Pennsylvania |
Disclosure:
|
Dr. Kaplan
previously received research or grant support from Bayer
Healthcare. That relationship was terminated at least 12
months ago. His presentation has been peer reviewed for
any bias.
|
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Eisai, and Exelixis
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |